Dimerix Enrolls First Kidney Patient to Open Label Extension Study; Shares Fall 6%
Dimerix (ASX:DXB) enrolled the first patient to an open-label extension study for its kidney disease medication DMX-200, according to a Tuesday filing with the Australian bourse.
The patient completed the pharmaceutical firm's phase three trial investigating the use of DMX-200 to treat focal segmental glomerulosclerosis, a condition that may lead to kidney scarring, the filing added.
The patient will now continue their treatment for up to two years as part of the open-label study, the filing stated.
Dimerix's shares fell 6% in recent trade.
Price (AUD): $0.38, Change: $-0.025, Percent Change: -6.17%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。